Nomogram Prediction for the Risk of Diabetic Foot in Patients With Type 2 Diabetes Mellitus

被引:12
作者
Wang, Jie [1 ]
Xue, Tong [2 ]
Li, Haopeng [1 ]
Guo, Shuai [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Orthoped Surg, Xian, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Neonatol, Xian, Peoples R China
关键词
type 2 diabetes mellitus (T2DM); diabetic foot; orthopedics; nomogram; individual risk prediction model; DENSITY-LIPOPROTEIN; PROSTACYCLIN; NEUROPATHY; SMOKING; LDL;
D O I
10.3389/fendo.2022.890057
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsTo develop and validate a nomogram prediction model for the risk of diabetic foot in patients with type 2 diabetes mellitus (T2DM) and evaluate its clinical application value. MethodsWe retrospectively collected clinical data from 1,950 patients with T2DM from the Second Affiliated Hospital of Xi'an Jiaotong University between January 2012 and June 2021. The patients were divided into training cohort and validation cohort according to the random number table method at a ratio of 7:3. The independent risk factors for diabetic foot among patients with T2DM were identified by multivariate logistic regression analysis. Then, a nomogram prediction model was developed using the independent risk factors. The model performances were evaluated by the area under the receiver operating characteristic curve (AUC), calibration plot, Hosmer-Lemeshow test, and the decision curve analysis (DCA). ResultsMultivariate logistic regression analysis indicated that age, hemoglobin A1c (HbA1c), low-density lipoprotein (LDL), total cholesterol (TC), smoke, and drink were independent risk factors for diabetic foot among patients with T2DM (P < 0.05). The AUCs of training cohort and validation cohort were 0.806 (95% CI: 0.775 similar to 0.837) and 0.857 (95% CI: 0.814 similar to 0.899), respectively, suggesting good discrimination of the model. Calibration curves of training cohort and validation cohort showed a favorable consistency between the predicted probability and the actual probability. In addition, the P values of Hosmer-Lemeshow test for training cohort and validation cohort were 0.826 and 0.480, respectively, suggesting a high calibration of the model. When the threshold probability was set as 11.6% in the DCA curve, the clinical net benefits of training cohort and validation cohort were 58% and 65%, respectively, indicating good clinical usefulness of the model. ConclusionWe developed and validated a user-friendly nomogram prediction model for the risk of diabetic foot in patients with T2DM. Nomograms may help clinicians early screen and identify patients at high risk of diabetic foot.
引用
收藏
页数:9
相关论文
共 47 条
[1]   The diabetic foot [J].
Ahmad, Jamal .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2016, 10 (01) :48-60
[3]  
Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI [10.2337/dc10-s062, 10.2337/dc09-S062]
[4]  
Azmi Shazli, 2019, F1000Res, V8, DOI 10.12688/f1000research.17118.1
[5]   The diabetic foot: Pathophysiology, evaluation, and treatment [J].
Bandyk, Dennis F. .
SEMINARS IN VASCULAR SURGERY, 2018, 31 (2-4) :43-48
[6]   Evidence-based protocol for diabetic foot ulcers [J].
Brem, Harold ;
Sheehan, Peter ;
Rosenberg, Harvey. J. ;
Schneider, Jillian S. ;
Boulton, Andrew J. M. .
PLASTIC AND RECONSTRUCTIVE SURGERY, 2006, 117 (07) :193S-209S
[7]   The pathobiology of diabetic complications - A unifying mechanism [J].
Brownlee, M .
DIABETES, 2005, 54 (06) :1615-1625
[8]   Smoking and smoking cessation-The relationship between cardiovascular disease and lipoprotein metabolism: A review [J].
Campbell, Sara Chelland ;
Moffatt, Robert J. ;
Stamford, Bryant A. .
ATHEROSCLEROSIS, 2008, 201 (02) :225-235
[9]   The inducible nitric-oxide synthase modulates endothelin-1-dependent release of prostacyclin and inhibition of platelet aggregation ex vivo in the mouse [J].
Carrier, Emilie ;
Brochu, Isabelle ;
de Brum-Fernandes, Artur J. ;
D'Orleans-Juste, Pedro .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (03) :972-978
[10]  
Cerf Marlon E, 2013, Front Endocrinol (Lausanne), V4, P37, DOI 10.3389/fendo.2013.00037